Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Oxford Lane Capital Corp (OXLC) Price & Performance

Amylx Pharmaceuticals IncTrade
Oxford Lane Capital CorpTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Oxford Lane Capital Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Oxford Lane Capital Corp trades at $9.52 (market cap $909.61M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 2.9× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 25.76% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXOXLC
Market Cap
$2.64B$909.61M
Sector
HealthFinancials
52-Week High
$24.19$18.75
52-Week Low
$7.82$8.15
Enterprise Value
$2.39B
Dividend Yield
25.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.

The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.

Oxford Lane Capital Corp

OXLC trades at $9.51, up 2.59% today, with a bullish technical signal from moving averages but a neutral RSI. The stock shows mixed fundamentals: a low P/B of 0.88 suggests undervaluation, but negative ROE and ROA highlight profitability challenges. Recent earnings misses and a sharp revenue decline in 2026 contrast with consistent $0.20 monthly dividends. News sentiment is divided, with some highlighting high yield opportunities and others warning of NAV erosion and unsustainable payouts.

The outlook is cautious due to earnings volatility and high yield sustainability concerns. Opportunities include deep discount to book value and analyst buy ratings, but risks involve persistent net income losses, negative cash flow from operations, and potential dividend cuts if NAV declines continue.

Returns comparison

Trailing returns across standard periods

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Oxford Lane Capital Corp

Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.

Read more on OXLC